Daily Vitamin C Linked to Better Survival in Blood Cancer

People with precancerous blood disorders might have a new reason for hope, and it comes in a form as simple as a daily vitamin.

Researchers at Van Andel Institute just completed the first randomized clinical trial testing whether vitamin C could help patients with conditions that often lead to leukemia. The results surprised even the scientists conducting the study.

The EVITA trial followed 109 patients with precancerous blood disorders or early stage blood cancers for three years. Half received 1,000 mg of vitamin C daily for one year, while the other half got a placebo. Neither patients nor doctors knew who received what until the study ended.

Patients taking vitamin C experienced fewer complications during treatment. They also showed changes in immune signaling molecules that typically point toward better health outcomes.

The most encouraging discovery came during follow up. After approximately three years, patients who had taken vitamin C were significantly more likely to be alive than those who received the placebo.

Scientists chose to focus on vitamin C because people with blood disorders and blood cancers often have persistently low levels of this essential nutrient. The body needs vitamin C to keep the immune system strong, heal wounds, and protect cells from damage.

These conditions, called clonal cytopenia of undetermined significance and myelodysplastic syndrome, become more common as people age. Right now, doctors have no approved treatments to stop them from turning into acute myeloid leukemia, an aggressive cancer that resists many therapies.

The trial tested a dose available in most over the counter supplements. Previous studies had looked at vitamin C given through an IV for solid tumors, making this research the first to explore whether a daily pill might help prevent blood cancer progression.

Why This Inspires

This research represents a shift in how doctors think about cancer treatment. Instead of waiting for cancer to develop and then fighting it, scientists are learning to intervene earlier when conditions are still precancerous.

The idea that something as accessible and affordable as vitamin C could make a real difference feels almost too good to be true. Yet the rigorous design of this trial, with its double blind approach and placebo control, gives these findings serious weight.

Dr. Peter Jones from Van Andel Institute explains that vitamin C may help restore normal function in blood cells before they become cancerous. The research team is now working to understand exactly how this common vitamin interacts with precancerous cells.

Dr. Kirsten Grønbæk, who led the international effort, emphasizes that these are preliminary findings. The team needs to conduct a larger phase 3 trial before doctors can make definitive recommendations. But the groundwork is laid, and the early results shine with promise.

For millions of older adults who face increased risk of these blood disorders, this research offers something precious: a potential path forward that's safe, simple, and within reach.